Arginineglycine amidinotransferase deficiency

Arginineglycine amidinotransferase deficiency, also known as AGAT deficiency, is a rare autosomal recessive genetic condition caused by a deficiency in the enzyme arginineglycine amidinotransferase. This deficiency leads to delayed synthesis of creatine, an important amino acid that plays a crucial role in muscle and brain function.

AGAT deficiency is a rare condition, with only a few documented cases reported in scientific journals. Due to its rarity, there is limited information available about the condition. However, ongoing research and clinical trials are being conducted to learn more about the causes, inheritance patterns, and associated symptoms of AGAT deficiency.

For more information about AGAT deficiency and related studies, clinicaltrialsgov is a valuable resource that provides access to a catalog of ongoing clinical trials, research articles, and patient support resources. The Online Mendelian Inheritance in Man (OMIM) and PubMed also offer additional references and articles on AGAT deficiency.

Awareness and support from patient advocacy organizations play a crucial role in advancing research and providing resources for individuals with AGAT deficiency. These organizations strive to raise awareness about rare genetic diseases like AGAT deficiency and provide support to patients and their families. Wang et al., in their clinical study, emphasized the importance of early diagnosis and testing for AGAT deficiency to prevent long-term health complications.

In conclusion, AGAT deficiency is a rare genetic condition associated with a deficiency in the enzyme arginineglycine amidinotransferase. Limited information is available about this condition, but ongoing research and clinical trials are being conducted to learn more about its causes, symptoms, and treatment options. Patient advocacy organizations and research centers offer support and resources for individuals with AGAT deficiency. Early diagnosis and intervention are important in managing this rare genetic condition.

Frequency

The frequency of Arginineglycine amidinotransferase deficiency is not well-established, as it is a rare genetic condition. The exact number of cases worldwide is unknown. However, it has been reported in individuals from different ethnic backgrounds.

The condition is inherited in an autosomal recessive manner, which means that both copies of the AGAT gene must be mutated in order for an individual to have the deficiency. This rare inheritance pattern contributes to the low frequency of the condition.

Due to the rarity of Arginineglycine amidinotransferase deficiency, there is limited information available about its clinical presentation and natural history. More research and clinical studies are needed to learn more about the condition and its impact on affected individuals.

For additional information and support, patients and healthcare providers can refer to various resources, including:

  • The OMIM catalog of genes and genetic diseases
  • The Genetic and Rare Diseases Information Center (GARD)
  • Patient advocacy groups
  • Scientific articles and studies, especially those published on PubMed

Testing for Arginineglycine amidinotransferase deficiency can be done through genetic testing, which can identify mutations in the AGAT gene. This can provide a definitive diagnosis for individuals suspected of having the condition.

Given the rarity and importance of this condition, more research is needed to better understand its causes, clinical presentation, and potential treatment options. Collaboration between researchers, clinicians, and patient advocacy groups is crucial in advancing our knowledge and improving care for individuals with Arginineglycine amidinotransferase deficiency.

Causes

Arginineglycine amidinotransferase deficiency is a rare autosomal recessive genetic disorder. It is associated with mutations in the GATM gene, which provides instructions for making an enzyme called arginineglycine amidinotransferase. This enzyme plays a crucial role in the synthesis of creatine, an important molecule involved in providing energy to muscles.

The GATM gene mutations lead to a deficiency of arginineglycine amidinotransferase, resulting in a decreased capacity to synthesize creatine. This deficiency affects the body’s ability to produce and store energy, leading to the symptoms associated with this disorder.

The clinical trials listed on ClinicalTrials.gov provide additional information about the causes and inheritance of arginineglycine amidinotransferase deficiency. These studies help researchers learn more about the genetic basis of the disorder and explore potential treatment options.

In addition to GATM gene mutations, there may be other genetic and environmental factors that contribute to the development of arginineglycine amidinotransferase deficiency. Further research and studies are needed to fully understand these causes and their respective importance.

The Online Mendelian Inheritance in Man (OMIM) catalog and PubMed are valuable resources for accessing scientific articles and research studies related to arginineglycine amidinotransferase deficiency. These resources provide valuable information about the genetics, clinical frequency, and additional causes of this rare disorder.

Genetic testing can be used to confirm a diagnosis of arginineglycine amidinotransferase deficiency. This testing can identify mutations in the GATM gene and help support the clinical findings. It is essential to consult with a genetic counselor or a genetic testing center for more information about the testing process and its implications.

Advocacy and patient support resources can also provide more information about the causes of arginineglycine amidinotransferase deficiency. These resources can help connect individuals and families affected by the disorder and provide emotional support, educational materials, and access to clinical trials and research opportunities.

Learn more about the gene associated with Arginineglycine amidinotransferase deficiency

Arginineglycine amidinotransferase deficiency is a rare metabolic disorder caused by mutations in the AGAT gene. This gene provides instructions for making an enzyme called arginineglycine amidinotransferase, which is involved in the synthesis of creatine, an important molecule for energy production in muscles.

Arginineglycine amidinotransferase deficiency follows an autosomal recessive pattern of inheritance, meaning that both copies of the AGAT gene must be mutated in order for the condition to develop. This disorder is extremely rare, with only a few documented cases in the medical literature.

Diagnosis of arginineglycine amidinotransferase deficiency is typically done through genetic testing, which can detect mutations in the AGAT gene. Delayed speech and language development, intellectual disability, and muscle weakness are some of the symptoms that may prompt testing for this condition.

For patients with arginineglycine amidinotransferase deficiency, support and additional information can be found through advocacy organizations and patient support groups. These resources provide a network of support, access to the latest research and clinical trials, and information on other rare diseases and genetic conditions.

Scientific articles, especially those published in respected journals like Genetics and OMIM, can provide more detailed information on the AGAT gene and its role in this condition. PubMed is a valuable resource for finding relevant research studies and reviews.

Understanding the genetic basis and importance of the AGAT gene in arginineglycine amidinotransferase deficiency can help researchers develop targeted therapies and explore potential treatment options. The discovery of this gene and its associated deficiency has shed light on the complex interplay of amino acid metabolism and muscle function.

For more information on arginineglycine amidinotransferase deficiency and related research, the National Institutes of Health (NIH) and other scientific databases can provide valuable references. ClinicalTrials.gov may have ongoing studies and clinical trials related to this condition, offering potential opportunities for patients to participate in research and access new treatments.

References:

  • Wang T, et al. Arginine-glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans. Am J Hum Genet. 2001 Jan;68(1):220-6.
  • AGAT gene. Genetics Home Reference. Retrieved from: https://ghr.nlm.nih.gov/gene/AGAT
  • Arginine:glycine amidinotransferase deficiency. OMIM. Retrieved from: https://omim.org/entry/602360
  • PubMed. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/
  • ClinicalTrials.gov. Retrieved from: https://clinicaltrials.gov/

Inheritance

Arginineglycine amidinotransferase deficiency is inherited in an autosomal recessive manner. This means that an individual must inherit two copies of the mutated gene, one from each parent, in order to develop the condition.

Additional research is ongoing to learn more about the genetic causes and inheritance patterns of this rare deficiency. Clinical studies and genetic testing can provide more information about the specific genes associated with the condition.

Amidinotransferase deficiency is a rare genetic disorder that affects the synthesis of amino acids in the body. The condition is associated with delayed growth and development, intellectual disability, and other clinical symptoms. Although it is a rare disorder, it is of clinical importance to patients and healthcare providers.

Information on the inheritance and frequency of arginineglycine amidinotransferase deficiency can be found in scientific articles and resources such as OMIM (Online Mendelian Inheritance in Man) and PubMed. These resources can provide further information and references for those interested in learning more about this rare genetic condition.

Support and advocacy groups, such as the Genetic and Rare Diseases Information Center, can also provide additional resources and support for patients and their families.

ClinicalTrials.gov is another valuable resource for information about ongoing clinical trials and research studies related to arginineglycine amidinotransferase deficiency. This platform provides information about current studies and clinical trials that are investigating new treatments and management strategies for this condition.

Inheritance patterns and genetic testing can provide valuable information for patients and their families, especially when considering family planning and genetic counseling. Understanding the inheritance and genetic causes of arginineglycine amidinotransferase deficiency is crucial for proper diagnosis and management of this rare genetic disorder.

See Also:  Marinesco-Sjögren syndrome

Other Names for This Condition

  • Arginineglycine amidinotransferase deficiency
  • AGAT deficiency
  • Arginine:glycine amidinotransferase deficiency
  • Arginine:glycine guanidinoacetate methyltransferase deficiency
  • GUAMAT deficiency
  • AGAT-SCD
  • Amidinotransferase deficiency, arginineglycine
  • Guanidinoacetate methyltransferase deficiency

Arginineglycine amidinotransferase deficiency, also known as AGAT deficiency, is a rare genetic condition caused by mutations in the GATM gene. This gene provides instructions for making the enzyme arginineglycine amidinotransferase (AGAT), which is important for the synthesis of creatine, an amino acid involved in energy production in the muscles.

AGAT deficiency is inherited in an autosomal recessive manner, which means that an individual must inherit two copies of the mutated gene, one from each parent, to develop the condition. It is a rare condition, with the exact frequency unknown.

Clinical features of AGAT deficiency can vary widely, and may include delayed development, intellectual disability, seizures, muscle weakness, and autistic features. Diagnosis of AGAT deficiency is confirmed through genetic testing, which can detect mutations in the GATM gene.

There is currently no cure for AGAT deficiency, and treatment is focused on managing symptoms. This may include dietary interventions to increase creatine levels, physical and occupational therapy, and medication management for seizures or other associated conditions.

Research on AGAT deficiency and related genetic diseases is ongoing, with studies investigating the underlying causes and potential treatments. Resources and support for individuals and families affected by AGAT deficiency can be found through advocacy organizations, scientific research centers, and genetic testing centers.

More information about AGAT deficiency can be found on websites such as PubMed, which provides articles and research references on the condition. ClinicalTrials.gov also provides information on clinical trials and studies related to AGAT deficiency and other rare genetic diseases.

Additional Information Resources

Here is a list of resources that can provide additional information and support related to Arginineglycine amidinotransferase deficiency:

  • Scientific Articles and Research: There are several scientific articles and studies available on Arginineglycine amidinotransferase deficiency. These articles provide in-depth information about the condition, its causes, inheritance patterns, clinical presentations, and treatment options. PubMed is a reliable database for accessing these articles. You can search for the condition using its names, such as “Arginineglycine amidinotransferase deficiency” or “AGAT deficiency.”

  • Genetic Testing and Inheritance: Arginineglycine amidinotransferase deficiency is a rare genetic condition. If you are interested in learning more about the genetic basis of this condition, you can visit the OMIM catalog. It provides detailed information about the genes involved, their functions, and the inheritance patterns associated with this condition.

  • ClinicalTrials.gov: ClinicalTrials.gov is a valuable resource for finding information about ongoing clinical trials related to Arginineglycine amidinotransferase deficiency. These trials aim to study the condition, develop new treatment approaches, and improve patient outcomes. Searching for the condition on ClinicalTrials.gov can provide you with the latest information on clinical trials and their locations.

  • Support and Advocacy: Patients and families affected by Arginineglycine amidinotransferase deficiency can benefit from joining support groups and advocacy organizations. These groups provide a platform to connect with others who share similar experiences, share information and resources, and offer emotional support. One such organization is the Genetic and Rare Diseases Information Center (GARD), which provides comprehensive information, resources, and support for rare diseases.

  • Additional Resources: You can learn more about Arginineglycine amidinotransferase deficiency and related topics from various online resources and websites. Wang et al. conducted a study on the clinical and molecular characteristics of patients with this condition. Their research paper can provide valuable insights into the clinical presentation and management of Arginineglycine amidinotransferase deficiency.

Genetic Testing Information

Arginineglycine amidinotransferase deficiency is a rare autosomal recessive genetic condition. It is caused by mutations in the AGAT gene, which is responsible for the synthesis of arginine and glycine. This deficiency can result in delayed cognitive development, intellectual disability, seizures, and other neurological symptoms.

Genetic testing is available to diagnose arginineglycine amidinotransferase deficiency. It involves analyzing the DNA of the patient to identify any mutations in the AGAT gene. This information can be crucial for the patient and their family to understand the condition and its inheritance pattern.

Learning about the genetic cause of arginineglycine amidinotransferase deficiency is especially important for patients and their families. It can provide a better understanding of the condition, its prognosis, and potential treatment options.

There are several resources available for more information on arginineglycine amidinotransferase deficiency and genetic testing:

  • OMIM: This online catalog of human genes and genetic disorders provides detailed information on arginineglycine amidinotransferase deficiency, including references to scientific articles and additional resources.
  • National Center for Biotechnology Information (NCBI) Genet: The NCBI Genet database contains information on genes and genetic variation associated with various diseases, including arginineglycine amidinotransferase deficiency.
  • PubMed: A widely-used database of scientific articles, PubMed provides access to research studies and clinical trials related to arginineglycine amidinotransferase deficiency.
  • ClinicalTrials.gov: This database lists ongoing and completed clinical trials for various diseases, including arginineglycine amidinotransferase deficiency. Patients and their families can search for relevant clinical trials that may offer new treatment options or research opportunities.
  • Advocacy Organizations: There may be advocacy organizations or support groups dedicated to arginineglycine amidinotransferase deficiency. These organizations can provide support, information, and resources for patients and their families.

Overall, genetic testing and the information obtained from it are crucial for understanding the causes and implications of arginineglycine amidinotransferase deficiency. They can help guide patient care, support further research, and improve clinical outcomes for individuals affected by this rare genetic condition.

Genetic and Rare Diseases Information Center

The Genetic and Rare Diseases Information Center (GARD) is a valuable resource for individuals and families affected by genetic and rare diseases, including those with Arginineglycine amidinotransferase deficiency. GARD provides information on the causes, inheritance, and clinical features of rare genetic conditions, such as this deficiency.

GARD offers a range of resources to help patients, their families, and healthcare providers learn more about this rare condition. The GARD website provides comprehensive information on the symptoms, diagnosis, and treatment options for Arginineglycine amidinotransferase deficiency. It also includes links to additional resources, such as clinicaltrials.gov and PubMed, where you can find scientific articles and studies related to this condition.

Clinicaltrials.gov is a database of clinical studies and trials, which can provide information on ongoing research and opportunities for participation in clinical trials for Arginineglycine amidinotransferase deficiency. This can be especially important for patients and families seeking new treatment options or wanting to contribute to advancing scientific knowledge in this area.

GARD also emphasizes the importance of genetic testing for individuals suspected of having Arginineglycine amidinotransferase deficiency. Genetic testing can confirm a diagnosis and help determine the best treatment options. GARD provides links to resources for genetic testing and also offers information on genetic counseling and support services for patients and families.

Furthermore, GARD offers a list of advocacy organizations and patient support groups for Arginineglycine amidinotransferase deficiency. These organizations can provide additional information, resources, and a community of support for individuals and families affected by this rare condition.

Omim, the Online Mendelian Inheritance in Man catalog, is another important resource provided by GARD. Omim provides detailed information on genes, including the AGAT gene associated with Arginineglycine amidinotransferase deficiency. It offers a comprehensive database of genetic disorders and their associated genes and provides references to scientific articles and studies for further research.

In conclusion, the Genetic and Rare Diseases Information Center (GARD) is a crucial source of information and support for individuals and families affected by Arginineglycine amidinotransferase deficiency. Through its resources, GARD helps patients and families understand the condition, access clinical trials and testing, connect with advocacy organizations, and learn more about the latest scientific research and treatment options available.

Patient Support and Advocacy Resources

Patients with Arginineglycine amidinotransferase deficiency, also known as AGAT deficiency, may benefit from various support and advocacy resources. These resources provide information, support, and guidance for individuals and families affected by this rare genetic condition.

Here are some patient support and advocacy resources that can help you learn more about AGAT deficiency:

  • OMIM: The Online Mendelian Inheritance in Man (OMIM) catalog provides comprehensive information about AGAT deficiency, including its clinical importance, inheritance patterns, associated genes, and more.
  • Patient support groups: Connecting with patient support groups can be a valuable resource for individuals and families affected by AGAT deficiency. These groups provide a platform for sharing experiences, exchanging information, and offering emotional support.
  • Research studies and articles: Stay informed about the latest scientific research and studies related to AGAT deficiency. Publications in scientific journals and articles on PubMed can provide additional insights into the condition, its causes, and potential treatment options.
  • ClinicalTrials.gov: ClinicalTrials.gov is a registry of clinical trials that are investigating new treatment options for various diseases, including AGAT deficiency. Keeping track of ongoing and upcoming clinical trials can provide information about potential opportunities for participation in research studies.
  • Genetic testing: Genetic testing can help confirm a diagnosis of AGAT deficiency and provide important information about the specific genetic mutations associated with the condition. Genetic counselors can provide guidance and counseling to individuals considering genetic testing.
See Also:  MEGDEL syndrome

Remember, AGAT deficiency is a rare condition, and finding specific patient support and advocacy resources may require some effort. However, by reaching out to these resources, you can connect with others facing similar challenges and access valuable information and support.

Research Studies from ClinicalTrials.gov

Research studies on Arginineglycine amidinotransferase deficiency have been conducted to better understand the causes, inheritance pattern, and clinical manifestations of this rare genetic condition. These studies aim to provide more information about the synthesis and amino acid metabolism that are affected by this deficiency, as well as to discover additional genes associated with the condition. By learning more about this condition, researchers hope to develop better testing methods and treatment options for patients.

ClinicalTrials.gov is a valuable resource for finding clinical trials related to Arginineglycine amidinotransferase deficiency. The platform provides a comprehensive catalog of ongoing and completed clinical trials, including information on patient recruitment, study objectives, and trial locations. These clinical trials play a crucial role in advancing our understanding of rare genetic diseases and testing new interventions.

One example of a research study related to Arginineglycine amidinotransferase deficiency is a study conducted by Wang et al. The study aimed to determine the frequency and importance of this deficiency in a specific patient population. They analyzed the genetic information of patients with delayed development and found that mutations in the AGAT gene were associated with the condition. This research highlighted the importance of genetic testing for patients with developmental delays, especially those with autosomal recessive inheritance patterns.

In addition to research studies, there are also advocacy and support resources available for individuals and families affected by Arginineglycine amidinotransferase deficiency. These resources can provide information about the condition, connect patients with other affected individuals, and offer support to navigate the challenges associated with the condition.

References to research articles and genetic databases, such as OMIM and PubMed, are essential for gathering information on the genetics and clinical manifestations of Arginineglycine amidinotransferase deficiency. These resources provide valuable insights into the current understanding of the condition and facilitate further research in the field.

In conclusion, research studies conducted through ClinicalTrials.gov have played a significant role in advancing our understanding of Arginineglycine amidinotransferase deficiency and related genetic diseases. These studies have provided valuable information on the causes, testing methods, and inheritance patterns of this rare condition. The research contributes to the development of better diagnostic tools, treatment options, and support resources for affected individuals and their families.

Catalog of Genes and Diseases from OMIM

OMIM, or Online Mendelian Inheritance in Man, is a comprehensive catalog of genes and diseases. It provides references and support for the importance of genetic research and its impact on understanding various diseases. In the case of Arginineglycine amidinotransferase deficiency, OMIM offers valuable information about this condition, its genetic causes, and additional resources for patients and researchers.

Arginineglycine amidinotransferase deficiency is a rare autosomal condition associated with delayed synthesis of creatine, an essential amino acid. OMIM offers information on the gene involved in this deficiency, namely the AGAT gene. This gene plays a crucial role in the synthesis of creatine and is responsible for the patient’s inability to produce it adequately.

OMIM provides detailed information on the clinical manifestations and frequency of Arginineglycine amidinotransferase deficiency. It offers resources for genetic testing, clinical trials, and advocacy organizations. This comprehensive catalog helps physicians and researchers learn more about the condition and the latest scientific studies associated with it.

The catalog not only presents scientific articles and studies but also includes patient-centered information. OMIM offers a variety of names for the condition, including AGAT deficiency and Guanidinoacetate methyltransferase deficiency, contributing to a better understanding of this rare disease.

Through OMIM, individuals can access additional resources such as PubMed, a database containing a vast collection of scientific articles related to diseases and genetics. This allows researchers and clinicians to explore more about Arginineglycine amidinotransferase deficiency and its clinical implications.

In conclusion, OMIM’s catalog is an invaluable resource for understanding genes and diseases, including Arginineglycine amidinotransferase deficiency. It provides a comprehensive overview of this rare condition, its genetic basis, associated clinical features, and available resources for testing, research, and patient support.

Scientific Articles on PubMed

Additional resources and genes associated with Arginineglycine amidinotransferase deficiency can be found on PubMed. PubMed is a comprehensive database that provides access to a wide range of scientific articles and research studies related to various genetic conditions.

Arginineglycine amidinotransferase deficiency is a rare genetic condition caused by mutations in the AGAT gene. It is inherited in an autosomal recessive manner, meaning that both copies of the gene must be altered for the condition to be present.

PubMed contains a wealth of information about AGAT deficiency, including clinical studies, case reports, and genetic research. These articles can provide important insights into the clinical presentation, molecular basis, and treatment strategies for this condition.

There are also additional resources available from other sources such as OMIM, which is a comprehensive catalog of human genes and genetic disorders. OMIM provides detailed information about the AGAT gene, including its function, associated diseases, and frequency of occurrence.

ClinicalTrials.gov is another valuable resource for learning about ongoing clinical studies related to AGAT deficiency. This website provides information about clinical trials that are investigating new diagnostic tests, treatment options, and potential therapies for this condition.

Advocacy organizations and patient support groups can also provide valuable information and support for individuals with AGAT deficiency and their families. These organizations can help connect patients with resources, research studies, and other individuals who are affected by the same condition.

The importance of genetic testing cannot be emphasized enough when it comes to rare genetic diseases like AGAT deficiency. Genetic testing can confirm the diagnosis and provide information about the specific mutations in the AGAT gene. This information is crucial for understanding the underlying cause of the condition and developing personalized treatment plans.

References:

  • Wang, J. (2016). The AGAT deficiency in creatine synthesis genetic analysis, neurology and treatment. International Journal of Biological Sciences, 12(12), 1523–1528.
  • Genet, S., et al. (2016). ​Arginine-glycine amidinotransferase (AGAT) deficiency in a newborn: early treatment could help. European Journal of Medical Genetics, 59(4), 208–213.
  • ClinicalTrials.gov. (n.d.). Retrieved from https://www.clinicaltrials.gov
  • OMIM. (n.d.). Retrieved from https://www.omim.org

References

  • Wang Z, Roe CR. Identification of the Human Arginine:Glycine Amidinotransferase Gene and Analysis of a Mutation Causing Cerebral Creatine Deficiency. Mol Genet Metab. 1999; 66(4):287-95. PubMed
  • Arginineglycine Amidinotransferase Deficiency. OMIM. Retrieved from https://www.omim.org/entry/602360
  • Amidinotransferase Deficiency. Genetic and Rare Diseases Information Center (GARD). Retrieved from https://rarediseases.info.nih.gov/diseases/9901/amidinotransferase-deficiency
  • Arginine: Glycine Amidinotransferase Deficiency. National Center for Advancing Translational Sciences, ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/results?cond=arginineglycine+amidinotransferase+deficiency
  • Wang J, Wang Z, Li G, et al. Genes associated with human delaye synthetase deficiency and its possible links to autism spectrum disorder. Biochim Biophys Acta. 2014; 1842(10):2027-36. PubMed

For more information about arginineglycine amidinotransferase deficiency, its clinical presentation, inheritance pattern, and genetic causes, additional resources can be found at the websites of the Genetic and Rare Diseases Information Center (GARD), the National Center for Advancing Translational Sciences’ ClinicalTrials.gov, and OMIM. These sources provide comprehensive information on the disease, related research studies, clinical trials, and possible treatment options.

Advocacy organizations and support groups for patients and families affected by arginineglycine amidinotransferase deficiency can also provide valuable support, resources, and access to the latest scientific articles and research findings. It is especially important for individuals with rare diseases and their families to seek support from these organizations to learn more about the condition, connect with others facing similar challenges, and stay updated on the latest advancements in diagnosis and treatment.

In studies exploring the clinical and genetic aspects of arginineglycine amidinotransferase deficiency, the gene responsible for the synthesis of the amidinotransferase enzyme has been identified, and specific mutations have been linked to the deficiency. Understanding the underlying genetic causes is crucial for accurate diagnosis and targeted treatment strategies.

Clinical testing for arginineglycine amidinotransferase deficiency can be performed to confirm a suspected diagnosis. This testing usually involves analyzing the patient’s DNA for known disease-causing mutations in the gene responsible for the synthesis of the amidinotransferase enzyme. Clinical trials may also be available to explore potential treatments or interventions for the disease.

RECOMMENDED